Shares of Swedish drug-delivery company Nanexa exploded higher Friday after the small biotech landed a licensing agreement worth as much as $1.33 billion with Novo Nordisk, the pharmaceutical heavyweight behind blockbuster obesity drugs Wegovy and Ozempic.
Nanexa shares surged more than 100% in Stockholm. the company announced Thursday evening that it had entered into a global exclusive licensing and collaboration agreement with Novo covering its PharmaShell drug-delivery technology.